Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
5QajwQ5t2Em4jmX1
Listen
